Recent evolution of surgical treatment for gastric cancer in Korea

Ji Yeong An, Jae Ho Cheong, Woo Jin Hyung, Sung Hoon Noh

Research output: Contribution to journalArticle

20 Citations (Scopus)

Abstract

Gastric cancer is the most common malignancy and the incidence is steadily increasing in Korea. The principal treatment modality for gastric cancer is surgical extirpation of tumor along with draining lymph nodes. Gastrectomy with D2 lymph node dissection has been well established as a standard of surgery and improved the survival of gastric cancer patients. Recently, technological advances are drastically reshaping the landscape of surgical treatment of gastric cancer. One of the most notable trends is that minimal access surgery becomes dominating the treatment of early stage diseases. For advanced diseases, the standard access surgery is considered a reference treatment. Although there is a pilot study underway to evaluate the feasibility of the application of minimal access surgery to advanced gastric cancer (AGC), the evidence for oncological safety is not yet provided sufficiently. Based on the recent randomized controlled trials, the extent of surgery for AGC has re-defined as para-aortic lymph node dissection dose not add any survival benefit while increasing surgery- related morbidities. In addition, it is now accepted as a standard operation omitting unnecessary procedures such as splenectomy and/or distal pancreatectomy for prophylactic lymph node dissection. Conceptual and technical innovation has contributed to decreasing morbidity and mortality without impairing oncological safety. All these recent advances in the field of gastric cancer surgery would be concluded in maximizing therapeutic index for gastric cancer while improving quality of life.

Original languageEnglish
Pages (from-to)1-6
Number of pages6
JournalJournal of Gastric Cancer
Volume11
Issue number1
DOIs
Publication statusPublished - 2011 Dec 1

Fingerprint

Korea
Stomach Neoplasms
Lymph Node Excision
Therapeutics
Morbidity
Unnecessary Procedures
Safety
Pancreatectomy
Survival
Splenectomy
Gastrectomy
Neoplasms
Randomized Controlled Trials
Lymph Nodes
Quality of Life
Mortality
Incidence

All Science Journal Classification (ASJC) codes

  • Oncology
  • Gastroenterology
  • Cancer Research

Cite this

An, Ji Yeong ; Cheong, Jae Ho ; Hyung, Woo Jin ; Noh, Sung Hoon. / Recent evolution of surgical treatment for gastric cancer in Korea. In: Journal of Gastric Cancer. 2011 ; Vol. 11, No. 1. pp. 1-6.
@article{8783515ed26a49eba72165ec89d7492c,
title = "Recent evolution of surgical treatment for gastric cancer in Korea",
abstract = "Gastric cancer is the most common malignancy and the incidence is steadily increasing in Korea. The principal treatment modality for gastric cancer is surgical extirpation of tumor along with draining lymph nodes. Gastrectomy with D2 lymph node dissection has been well established as a standard of surgery and improved the survival of gastric cancer patients. Recently, technological advances are drastically reshaping the landscape of surgical treatment of gastric cancer. One of the most notable trends is that minimal access surgery becomes dominating the treatment of early stage diseases. For advanced diseases, the standard access surgery is considered a reference treatment. Although there is a pilot study underway to evaluate the feasibility of the application of minimal access surgery to advanced gastric cancer (AGC), the evidence for oncological safety is not yet provided sufficiently. Based on the recent randomized controlled trials, the extent of surgery for AGC has re-defined as para-aortic lymph node dissection dose not add any survival benefit while increasing surgery- related morbidities. In addition, it is now accepted as a standard operation omitting unnecessary procedures such as splenectomy and/or distal pancreatectomy for prophylactic lymph node dissection. Conceptual and technical innovation has contributed to decreasing morbidity and mortality without impairing oncological safety. All these recent advances in the field of gastric cancer surgery would be concluded in maximizing therapeutic index for gastric cancer while improving quality of life.",
author = "An, {Ji Yeong} and Cheong, {Jae Ho} and Hyung, {Woo Jin} and Noh, {Sung Hoon}",
year = "2011",
month = "12",
day = "1",
doi = "10.5230/jgc.2011.11.1.1",
language = "English",
volume = "11",
pages = "1--6",
journal = "Journal of Gastric Cancer",
issn = "2093-582X",
publisher = "Korean Gastric Cancer Association",
number = "1",

}

Recent evolution of surgical treatment for gastric cancer in Korea. / An, Ji Yeong; Cheong, Jae Ho; Hyung, Woo Jin; Noh, Sung Hoon.

In: Journal of Gastric Cancer, Vol. 11, No. 1, 01.12.2011, p. 1-6.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Recent evolution of surgical treatment for gastric cancer in Korea

AU - An, Ji Yeong

AU - Cheong, Jae Ho

AU - Hyung, Woo Jin

AU - Noh, Sung Hoon

PY - 2011/12/1

Y1 - 2011/12/1

N2 - Gastric cancer is the most common malignancy and the incidence is steadily increasing in Korea. The principal treatment modality for gastric cancer is surgical extirpation of tumor along with draining lymph nodes. Gastrectomy with D2 lymph node dissection has been well established as a standard of surgery and improved the survival of gastric cancer patients. Recently, technological advances are drastically reshaping the landscape of surgical treatment of gastric cancer. One of the most notable trends is that minimal access surgery becomes dominating the treatment of early stage diseases. For advanced diseases, the standard access surgery is considered a reference treatment. Although there is a pilot study underway to evaluate the feasibility of the application of minimal access surgery to advanced gastric cancer (AGC), the evidence for oncological safety is not yet provided sufficiently. Based on the recent randomized controlled trials, the extent of surgery for AGC has re-defined as para-aortic lymph node dissection dose not add any survival benefit while increasing surgery- related morbidities. In addition, it is now accepted as a standard operation omitting unnecessary procedures such as splenectomy and/or distal pancreatectomy for prophylactic lymph node dissection. Conceptual and technical innovation has contributed to decreasing morbidity and mortality without impairing oncological safety. All these recent advances in the field of gastric cancer surgery would be concluded in maximizing therapeutic index for gastric cancer while improving quality of life.

AB - Gastric cancer is the most common malignancy and the incidence is steadily increasing in Korea. The principal treatment modality for gastric cancer is surgical extirpation of tumor along with draining lymph nodes. Gastrectomy with D2 lymph node dissection has been well established as a standard of surgery and improved the survival of gastric cancer patients. Recently, technological advances are drastically reshaping the landscape of surgical treatment of gastric cancer. One of the most notable trends is that minimal access surgery becomes dominating the treatment of early stage diseases. For advanced diseases, the standard access surgery is considered a reference treatment. Although there is a pilot study underway to evaluate the feasibility of the application of minimal access surgery to advanced gastric cancer (AGC), the evidence for oncological safety is not yet provided sufficiently. Based on the recent randomized controlled trials, the extent of surgery for AGC has re-defined as para-aortic lymph node dissection dose not add any survival benefit while increasing surgery- related morbidities. In addition, it is now accepted as a standard operation omitting unnecessary procedures such as splenectomy and/or distal pancreatectomy for prophylactic lymph node dissection. Conceptual and technical innovation has contributed to decreasing morbidity and mortality without impairing oncological safety. All these recent advances in the field of gastric cancer surgery would be concluded in maximizing therapeutic index for gastric cancer while improving quality of life.

UR - http://www.scopus.com/inward/record.url?scp=84866426651&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84866426651&partnerID=8YFLogxK

U2 - 10.5230/jgc.2011.11.1.1

DO - 10.5230/jgc.2011.11.1.1

M3 - Article

C2 - 22076195

AN - SCOPUS:84866426651

VL - 11

SP - 1

EP - 6

JO - Journal of Gastric Cancer

JF - Journal of Gastric Cancer

SN - 2093-582X

IS - 1

ER -